CRANBURY, N.J., Jan. 5 /PRNewswire-FirstCall/ -- Amicus Therapeutics today announced that President and Chief Executive Officer, John F. Crowley, will be presenting an overview of the Company's key strategic priorities for 2010 at the upcoming 28th Annual J.P. Morgan Healthcare Conference. Mr. Crowley's presentation is scheduled to begin on Monday, January 11 at 10:30 a.m. PST.
About Amicus Therapeutics
Amicus Therapeutics is developing orally-administered, small molecule drugs called pharmacological chaperones, a novel, first-in-class approach to treating a broad range of diseases including lysosomal storage disorders and diseases of neurodegeneration. Amicus' lead program is in Phase 3 for the treatment of Fabry disease.
CONTACT: Jenene Thomas of Amicus Therapeutics, +1-609-662-5084,
jthomas@amicustherapeutics.com
Web site: http://www.amicustherapeutics.com/
